Predict IQ is an innovative personalized behavioral health tool  utilizing the patented Genetic Addiction Risk Score (GARS) test to blend genetics, neuroscience, and AI for insights into brain wiring.

Based on Reward Deficiency Syndrome (RDS), a dopamine-related condition affecting reward, motivation, and emotional regulation, it draws from decades of research, NIH collaborations, and over 30 clinical trials. The at-home DNA swab analyzes key heavily researched gene variants to produce a digital report on traits like mood, focus, impulsivity, and addiction risk, aiding users and clinicians in proactive mental health decisions.

Predict IQ’s use of GARS makes it the global leading genetic platform for behavioral health, covering conditions like addiction, OCD, ADD/ADHD, PTSD, and impulsive behaviors under RDS. Complementing this, Synapta+ is a personalized neuro-nutrient formula, validated by NIH-funded studies, to balance dopamine and support brain health via nutrigenomics.

Key research highlights from the Clinical Dossier include:

• GARS and RDS Development: Neurogenetic basis for addiction, using polymorphic risks to predict RDS liabilities.
• High Risks in Opioid Users: GARS identifies elevated addiction vulnerabilities in clinical populations.
• Precision Management: Enhances reward connectivity with neuro-nutrients to address chemical imbalances.
• RDS as Unifying Theme: Links behavioral disorders through brain reward system changes.